Table 1. Baseline demographics of patients who have ever received TDF.
| Total (%) | aNumber with average S-Cr assessments ≥2 per year b(%) | |
|---|---|---|
| 2,425 (100) | 627 (25.9) | |
| Age at ART initiation (years) | median 35, IQR (30–42) | |
| ≤30 | 680 (28.0) | 151 (22.2) |
| 31–40 | 1,043 (43.0) | 256 (24.5) |
| 41–50 | 499 (20.6) | 149 (29.9) |
| >50 | 203 (8.4) | 71 (35.0) |
| Sex | ||
| Male | 1,668 (68.8) | 498 (29.9) |
| Female | 757 (31.2) | 129 (17.0) |
| Mode of HIV Exposure | ||
| Heterosexual contact | 1,671 (68.9) | 317 (19.0) |
| Homosexual contact | 452 (18.6) | 203 (44.9) |
| Injecting drug use | 164 (6.8) | 39 (23.8) |
| Other/unknown | 138 (5.7) | 68 (49.3) |
| Pre-ART weight (kg) | median = 54.9, IQR (48–63.8) | |
| ≤55 | 823 (33.9) | 162 (19.7) |
| >55 | 732 (30.2) | 244 (33.3) |
| Missing | 870 (35.9) | 221 (25.4) |
| Pre-ART viral load (copies/mL) | median = 100,000, IQR (34,388–270,000) | |
| ≤100,000 | 599 (24.7) | 217 (36.2) |
| >100,000 | 586 (24.2) | 225 (38.4) |
| Missing | 1,240 (51.1) | 185 (14.9) |
| Pre-ART CD4 (cells/μL) | median = 114, IQR (39–214) | |
| ≤50 | 634 (26.1) | 129 (20.3) |
| 51–100 | 311 (12.8) | 66 (21.2) |
| 101–200 | 519 (21.4) | 155 (29.9) |
| >200 | 561 (23.1) | 204 (36.4) |
| Missing | 400 (16.5) | 73 (18.3) |
| Initial ART Regimen | ||
| NRTI+NNRTI | 2,014 (83.1) | 402 (20.0) |
| NRTI+PI | 365 (15.1) | 211 (57.8) |
| Other | 46 (1.9) | 14 (30.4) |
| Hepatitis B co-infection | ||
| Negative | 1,593 (65.7) | 468 (29.4) |
| Positive | 334 (13.8) | 102 (30.5) |
| Not tested | 498 (20.5) | 57 (11.4) |
| Hepatitis C co-infection | ||
| Negative | 1,547 (63.8) | 472 (30.5) |
| Positive | 263 (10.8) | 58 (22.1) |
| Not tested | 615 (25.4) | 97 (15.8) |
| Previous AIDS | ||
| No | 1,470 (60.6) | 403 (27.4) |
| Yes | 955 (39.4) | 224 (23.5) |
| Country Income Level | ||
| Low + Lower Middle | 898 (37.0) | 137 (15.3) |
| Upper Middle | 1,196 (49.3) | 288 (24.1) |
| High | 331 (13.6) | 202 (61.0) |
| Pre-ART eGFR (ml/min per 1.73 m2) | ||
| <60 | 25 (1.0) | 15 (60.0) |
| ≥60 | 1166 (48.1) | 470 (40.3) |
| Missing | 1234 (50.9) | 142 (11.5) |
| cTDF use | ||
| Prior to TDF initiation | N/A | 293 (17.9) |
| After TDF initiation | N/A | 929 (38.3) |
Note:
a—Average calculated by the total number of serum creatinine assessments divided by the total follow-up time for each patient.
b—Proportion of patients having two serum creatinine assessments divided by the total number of patients in the same category.
c—Time-updated variable. The same patient can be counted in both categories.
TDF, tenofovir disoproxil fumarate; S-Cr, serum creatinine; ART, antiretroviral therapy; IQR, interquartile range; NRTI, nucleos(t)ide reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor